Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
StaatusVeel ei värvata
Sponsorid
Centre Hospitalier Universitaire de Nice

Märksõnad

Abstraktne

The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.

Kuupäevad

Viimati kinnitatud: 09/30/2019
Esmalt esitatud: 10/24/2019
Hinnanguline registreerumine on esitatud: 10/24/2019
Esmalt postitatud: 10/27/2019
Viimane värskendus on esitatud: 10/24/2019
Viimati värskendus postitatud: 10/27/2019
Õppe tegelik alguskuupäev: 12/31/2019
Eeldatav esmane lõpetamise kuupäev: 12/31/2021
Eeldatav uuringu lõpetamise kuupäev: 08/31/2022

Seisund või haigus

Diabetic Cardiomyopathies

Sekkumine / ravi

Dietary Supplement: Alpha-Lipoic Acid group

Dietary Supplement: placebo group

Faas

-

Käerühmad

ArmSekkumine / ravi
Active Comparator: Alpha-Lipoic Acid group
Dietary Supplement: Alpha-Lipoic Acid group
1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
Placebo Comparator: placebo group
Dietary Supplement: placebo group
1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks

Abikõlblikkuse kriteeriumid

Õppimiseks sobivad vanused 18 Years To 18 Years
Uuringuks kõlblikud soodAll
Võtab vastu tervislikke vabatahtlikkeJah
Kriteeriumid

Inclusion Criteria:

- Male or female adult age ≥ 18 years

- patient with diagnosed type 2 diabetes (history of pathological hyperglycemia according to WHO and HbA1c standards >7% or ongoing treatment with oral antidiabetic agents).

- Patients with stable cardiomyopathy (no hospitalization in cardiology in the month before inclusion) with a left ventricular ejection fraction (LVEF) <50%.

- patient who has signed an informed consent form

- For women of childbearing age: effective contraception followed for at least 3 months before the start of the study and agreeing to keep it for the duration of the study.

- affiliation to a social security scheme.

Exclusion Criteria:

subjects:

- With a coronary event in the year before inclusion.

- With symptoms of cardiac ischemia at inclusion.

- Pregnant or breastfeeding woman

- Severe renal insufficiency

- Using antioxidant molecules in the 6 months prior to inclusion.

- Using drugs that can activate PPARs (Fibrates, Telmisartan, Enalaprilat).

- Using anti-inflammatory drugs.

- Suffering from acute infectious diseases and inflammatory diseases.

- Hypersensitivity or a history of hypersensitivity reaction to gadoteric acid, meglumine or any drug containing gadolinium.

Non-inclusion criteria related to MRI:

- with an implanted vascular stent less than 6 weeks before the examination;

- carrier of an implanted biomedical device deemed "not safe" or "unsafe" in the list: http://www.mrisafety.com/TheList_search.asp;

- Beneficiary of an acquisition procedure that does not respect the conditions required by "conditional" use in a subject carrying an implanted biomedical material considered "conditional" in the list: http://www.mrisafety.com/TheList_search.asp;

- carrier of a ferromagnetic intraocular or intracranial foreign body close to the nerve structures;

- carrying biomedical equipment such as a cardiac, neural or sensory pacemaker (cochlear implant) or a ventricular bypass valve without medical and paramedical supervision trained to perform MRI in these subjects;

Tulemus

Esmased tulemusnäitajad

1. change of LVEF between before and after 12 weeks of treatment [12 weeks]

percentage of blood ejection before and after 12 weeks of treatment

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge